Changes in Insulin Resistance and Cardiovascular Risk Induced by PPARγ Activation have no Impact on RBP4 Plasma Concentrations in Nondiabetic Patients

Abstract

Retinol binding protein 4 (RBP4) has recently been suggested as a good biomarker for insulin resistance and the metabolic syndrome. With this study, we wanted to investigate the effect of pioglitazone (PIO) and simvastatin (SIMVA) on insulin resistance and RBP4 plasma concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications. The prospective, parallel, randomized, double-blind clinical trial was performed with 125 nondiabetic patients with increased cardiovascular risk (78 females, 47 males, age (mean±STD): 58.6±7.8 years, BMI: 30.8±4.2 kg/m²). They were randomized to either receive PIO (45 mg)+placebo, SIMVA (40 mg)+placebo, or PIO+SIMVA for 3 months. Key outcome measures were the HOMA_IR-Score, an oral glucose tolerance test, adiponectin, hsCRP, and RBP4 at baseline and endpoint. No correlation could be detected between the HOMA_IR values or the impaired fasting glucose tolerance status and RBP-4. Treatment with PIO alone or in combination with SIMVA resulted in a significant improvement of the HOMA_IR-Score and the adiponectin values, while no change in HOMA_IR and a decrease in adiponectin (p<0.05) were observed with SIMVA monotherapy. Reductions of hsCRP were seen in all three treatment arms (p<0.001). No changes of the plasma RBP4 concentrations were observed in any of the treatment groups (PIO: 35.6±7.2/36.3±8.7 ng/ml, PIO+SIMVA: 36.5±10.8/36.5±8 ng/ml, SIMVA: 36.1±8.1/36.6±11.1 ng/ml, all n.s. vs. baseline). Despite a partial or comprehensive improvement in insulin resistance and/or cardiovascular risk indicators in all treatment arms, no change in RBP4-levels could be observed. The regulation of RBP4 expression and secretion occurs through biochemical pathways independent from those influenced by pioglitazone or simvastatin.

metabolic syndrome - retinol binding protein 4 - cardiovascular risk

References

• 1 Blaner WS. Retinol binding protein: the serum transport protein for vitamin A.  Endocrinology. 1989;  10 308-316
• 2 Newcomer ME, Ong DE. Plasma retinol binding protein: structure and function of the prototypic lipocalin.  Biochim Biophys Acta. 2000;  1482 57-64
• 3 Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein contributes to insulin resistance in obesity and type 2 diabetes.  Nature. 2005;  436 356-362
• 4 Basualdo CG, Wein EE, Basu TK. Vitamin A (retinol) status of first nation adults with non-insulin-dependent diabetes mellitus.  J Am Coll Nutr. 1997;  16 39-45
• 5 Abahusain MA, Wright J, Dickerson JW, Vol EB de. Retinol, alpha-tocopherol and carotenoids in diabetes.  Eur J Clin Nutr. 1999;  53 630-635
• 6 Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects.  N Engl J Med. 2006;  354 2552-2563
• 7 Polonsky KS. Retinol-binding protein 4, insulin resistance, and type 2 diabetes.  N Engl J Med. 2006;  354 2596-2598
• 8 Perseghin G, Lattuda G, DeCobelli F, Esposito A, Belloni E, Canu T, Ragogna F. Serum retinol binding protein-4, leptin, and adiponectin concentrations are related to ectopic fat accumulation.  J Clin Endocrinol Metab. 2007;  92 4883-4884
• 9 Möhlig M, Weickert MO, Ghadamgahi E, Arafat AM, Spranger J, Pfeiffer AF, Schöfl C. Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome.  Eur J Endocrinol. 2008;  158 517-523
• 10 Pfützner A, Hohberg C, Lübben G, Pahler S, Pfützner AH, Kann P, Forst T. Pioneer study: PPARγ-activation results in an overall improvement of clinical and metabolic markers associated with insulin resistance independent from long-term glucose control.  Horm Metab Res. 2005;  37 510-515
• 11 Langenfeld M, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, Füllert S, Sachara C, Pfützner A. Pioglitazone decreases carotid intima-media thickness independent of glycemic control in patients with type 2 diabetes mellitus.  Circulation. 2005;  111 2525-2531
• 12 Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control – results from the pioneer study.  J Am Coll Card. 2005;  45 1925-1931
• 13 Pfützner A, Schneider C, Forst T. Pioglitazone – Cardiovascular aspects of an antidiabetic drug.  Exp Rev Cardiovasc Ther. 2006;  4 445-459
• 14 DREAM Trial investigators . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial.  Lancet. 2006;  368 1096-1105
• 15 Dormandy JA, Charbonnel B, Eckland EJA, Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. PROactive investigators . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.  Lancet. 2005;  366 1279-1289
• 16 Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.  Metabolism. 2007;  56 1418-1424
• 17 Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer 3rd HJ, Rashidi AA, MacGehee  Jr  RE, Fried SK, Kern PA. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.  J Clin Endocrinol Metab. 2007;  92 2590-2597
• 18 Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T. Anti-inflammatory effect of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitive CRP: The PIOSTAT study.  J Am Coll Cardiol. 2007;  49 290-297
• 19 Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C, Hanefeld M. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk–the PIOSTAT Study.  Metabolism. 2007;  56 491-496
• 20 Pfützner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, Köhler C, Hohberg C, Forst T. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk – results from the PIOSTAT study.  Horm Metab Res. 2007;  39 764-768
• 21 Pfützner A, Forst T. HsCRP as cardiovascular risk marker in patients with diabetes mellitus.  Diab Technol Ther. 2006;  8 28-36
• 22 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 23 Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden.  Diabet Med. 2000;  17 299-307
• 24 Schöndorf T, Maiworm A, Emmison N, Forst T, Pfützner A. Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk.  Clin Lab. 2005;  51 489-494
• 25 Yudkin JS. Inflammation, obesity and the metabolic syndrome.  Horm Metab Res. 2007;  39 707-709
• 26 Lamounier-Zepter V, Erhart-Bornstein M, Bornstein SR. Metabolic syndrome and the endocrine stress system.  Horm Metab Res. 2006;  38 437-441
• 27 Saely CH, Rein P, Drexel H. The metabolic syndrome and risk of cardiovascular disease and diabetes: experiences with the new diagnostic criteria from the international diabetes federation.  Horm Metab Res. 2007;  39 624-650
• 28 Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implication for future risk assessment.  Circulation. 2004;  109 1249-1353
• 29 Graham TE, Wason CJ, Blüher M, Kahn BB. Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects.  Diabetologia. 2007;  50 814-823
• 30 Hammarstedt A, Pihlajamäki J, Graham TE, Kainulainen S, Kahn BB, Laakso M, Smith U. High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects.  J Intern Med. 2008;  263 440-449
• 31 Yoshida A, Matsutani Y, Fukuchi Y, Saito K, Naito M. Analysis of the factors contributing to serum retinol binding protein and transthyretin in Japanese adults.  J Atheroscler Thromb. 2006;  13 209-215
• 32 Yoshida A, Kodama M, Nomura H, Naito M. Classification of lipoprotein profile by polyacrylamide gel disc electrophoresis.  Intern Med. 2003;  42 244-249
• 33 Janke J, Engli S, Boschmann M, Adams F, Böhnke J, Luft FC, Sharma AM, Jordan J. Retinol-binding protein 4 in human obesity.  Diabetes. 2006;  55 2805-2810
• 34 Graham TE, Kahn BB. Tissue-specific alterations of glucose transport and molecular mechanisms of intertissue communication in obesity and type 2 diabetes.  Horm Metab Res. 2007;  39 717-721

Correspondence